Katherine M. Bell‐McGuinn

Author

Also Known As

Bell‐McGuinn, Katherine M, K. Bell-McGuinn, K. M. Bell-McGuinn, K.M. Bell-McGuinn, Katherine Bell-McGuinn, Katherine Bell‐McGuinn, Katherine M Bell-McGuinn, Katherine M. Bell-McGuinn, Katherine M. Bell‐McGuinn

120

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University of Washington The University of Texas MD Anderson Cancer Center Cornell University Eli Lilly (United States)

About

Katherine M. Bell‐McGuinn is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	25	5.3K
2	Obstetrics	11	11	3K
3	Immunology	4	4	727
4	Health Sciences	3	3	58
5	Molecular Medicine	1	1	34

Katherine M. Bell‐McGuinn

Publications

Citations

H-Index

Page 1

	Year	Citations
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial M. William Audeh, James Carmichael, Richard T. Penson, The Lancet MedicineCancer ManagementGynecologyRecurrent Ovarian CancerPolymerase Inhibitor Olaparib	2010	2.3K
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, The Lancet Oncology MedicinePharmacologyPathologyCancer TreatmentOncology	2016	1.2K
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert L. Coleman, Gini F. Fleming, Mark F. Brady, New England Journal of Medicine	2019	886
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer Tanaya Shree, Oakley C. Olson, Benelita T. Elie, Genes & Development Breast OncologyS. MacrophagesChemoprevention StrategyImmunologyPathology	2011	527
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Journal of Clinical Oncology	2011	472
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients Paul Sabbatini, Takemasa Tsuji, Luis Ferran, Clinical Cancer Research	2012	272
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 Amit M. Oza, Anna V. Tinker, Ana Oaknin, Gynecologic Oncology	2017	272
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Gynecologic Oncology Brca2 MutationPhase Ii EvaluationGastrointestinal OncologyMedicineGynecology	2015	262
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer Katherine M. Bell‐McGuinn, Carolyn M. Matthews, Steffan N. Ho, Gynecologic Oncology Single-arm StudyPhase IiMedicinePrimary Peritoneal CancerImmunology	2011	164

Page 1